{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:48:51Z","timestamp":1781534931478,"version":"3.54.5"},"reference-count":47,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Most childhood neuromuscular disorders are caused by mutations causing abnormal expression or regulation of single genes or genetic pathways. The potential for gene therapy, gene editing and genetic therapies to ameliorate the course of these conditions is extraordinarily exciting, but there are significant challenges associated with their use, particularly with respect to safety, efficacy, cost and equity. Engagement with these novel technologies mandates careful assessment of the benefits and burdens of treatment for the patient, their family and their society. The examples provided by spinal muscular atrophy and Duchenne muscular dystrophy illustrate the potential value and challenges of gene and genetic therapies for paediatric neurological conditions. The cost and complexity of administration of these agents is a challenge for all countries. Jurisdictional variations in availability of newborn screening, genetic diagnostics, drug approval and reimbursement pathways, treatment and rehabilitation will affect equity of access, nationally and internationally. These challenges will best be addressed by collaboration by governments, pharma, clinicians and patient groups to establish frameworks for safe and cost-effective use of these exciting new therapies.<\/jats:p>","DOI":"10.1136\/archdischild-2020-320908","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T17:20:14Z","timestamp":1630344014000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Gene therapy for neuromuscular disorders: prospects and ethics"],"prefix":"10.1136","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6397-1910","authenticated-orcid":false,"given":"Monique M","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2022091204252522000_107.5.421.1","unstructured":"National Academies of Sciences, Engineering, and Medicine . Human genome editing: science, ethics, and governance. Washington, DC: The National Academies Press, 2017: 29\u201360."},{"key":"2022091204252522000_107.5.421.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706910"},{"key":"2022091204252522000_107.5.421.3","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.255"},{"key":"2022091204252522000_107.5.421.4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"2022091204252522000_107.5.421.5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu Rev Virol"},{"key":"2022091204252522000_107.5.421.6","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4593"},{"key":"2022091204252522000_107.5.421.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1978-5"},{"key":"2022091204252522000_107.5.421.8"},{"key":"2022091204252522000_107.5.421.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"2022091204252522000_107.5.421.10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"2022091204252522000_107.5.421.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"2022091204252522000_107.5.421.12","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp072"},{"key":"2022091204252522000_107.5.421.13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2009965"},{"key":"2022091204252522000_107.5.421.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"2022091204252522000_107.5.421.15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Neurol"},{"key":"2022091204252522000_107.5.421.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003454"},{"key":"2022091204252522000_107.5.421.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30374-9"},{"key":"2022091204252522000_107.5.421.18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum Gene Ther"},{"key":"2022091204252522000_107.5.421.19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0729"},{"key":"2022091204252522000_107.5.421.20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr"},{"key":"2022091204252522000_107.5.421.21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr"},{"key":"2022091204252522000_107.5.421.22","unstructured":"Solid Biosciences . Solid biosciences provides SGT-001 program update. Available: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-provides-sgt-001-program-update [Accessed 23 Feb 2021]."},{"key":"2022091204252522000_107.5.421.23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"2022091204252522000_107.5.421.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2889"},{"key":"2022091204252522000_107.5.421.25","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"2022091204252522000_107.5.421.26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"key":"2022091204252522000_107.5.421.27","article-title":"Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis","volume":"2","author":"Braun","year":"2014","journal-title":"Rare Dis"},{"key":"2022091204252522000_107.5.421.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79213"},{"key":"2022091204252522000_107.5.421.29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302984"},{"key":"2022091204252522000_107.5.421.30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11673"},{"key":"2022091204252522000_107.5.421.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821000116"},{"key":"2022091204252522000_107.5.421.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"2022091204252522000_107.5.421.33","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"2022091204252522000_107.5.421.34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"key":"2022091204252522000_107.5.421.35","first-page":"361","article-title":"The effectiveness and value of deflazacort and exon-skipping therapies for the management of Duchenne muscular dystrophy","volume":"26","author":"Agboola","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2022091204252522000_107.5.421.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"2022091204252522000_107.5.421.37","unstructured":"Institute for Clinical and Economic Review . Spinraza and Zolgensma for spinal muscular atrophy. effectiveness and value. Available: https:\/\/icer-review.org\/wp-ontent\/uploads\/2018\/07\/ICER_SMA_Final_Evidence_Report_040319.pdf [Accessed February 20 2021]."},{"key":"2022091204252522000_107.5.421.38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay9648"},{"key":"2022091204252522000_107.5.421.39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mus.27116","article-title":"Early experiences of nusinersen for the treatment of spinal muscular atrophy: results from a large survey of patients and caregivers","volume":"63","author":"Chen","year":"2021","journal-title":"Muscle Nerve"},{"key":"2022091204252522000_107.5.421.40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1813279"},{"key":"2022091204252522000_107.5.421.41","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","author":"Shih","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022091204252522000_107.5.421.42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/ijns6020035","article-title":"Implementing statewide newborn screening for new disorders: U.S. program experiences","volume":"6","author":"Kellar-Guenther","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"2022091204252522000_107.5.421.43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-190451","article-title":"Restore: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy - rationale and study design","volume":"7","author":"Finkel","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"2022091204252522000_107.5.421.44","article-title":"Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study","author":"Rudnicki","year":"2021","journal-title":"Neurotherapeutics"},{"key":"2022091204252522000_107.5.421.45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"2022091204252522000_107.5.421.46","unstructured":"Estepan I . Sarepta therapeutics Announces positive functional results from the SRP-9003 (MYO-101) gene therapy trial to treat limb-girdle muscular dystrophy type 2E, or Beta-Sarcoglycanopathy, 2019. Sarepta therapeutics, Inc. Investor relations. Available: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-positive-functional-results-srp [Accessed 13 Jun 2020]."},{"key":"2022091204252522000_107.5.421.47","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21732"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2020-320908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T11:31:40Z","timestamp":1662982300000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2020-320908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/archdischild-2020-320908"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2020-320908","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]}}}